recombinant protein vaccine + adenovirus vector vaccine

This drug entry refers to a heterologous sequential booster vaccination regimen for COVID-19, combining a recombinant protein subunit vaccine and an adenovirus vector vaccine. The regimen is being evaluated by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, specifically to investigate its ability to enhance immune responses in patients with metabolic associated fatty liver disease (MAFLD). The recombinant protein component typically utilizes a purified portion of the SARS-CoV-2 spike protein (often the receptor-binding domain) to stimulate the production of neutralizing antibodies. The adenovirus vector component uses a non-replicating viral vector (such as Adenovirus Type 5) to deliver the genetic sequence of the spike protein into host cells, thereby inducing both robust humoral and cellular (T-cell) immune responses. This sequential strategy aims to provide broader and more durable protection than homologous boosting, particularly in populations with underlying metabolic conditions that may impair vaccine efficacy.

Other names

sequential booster SARS-CoV-2 vaccinationheterologous prime-boost COVID-19 vaccinerecombinant protein and adenovirus vector sequential booster